4D-150 - (PRISM)

June 30, 2026: 4D Molecular Therapeutics (NASDAQ: FDMT) announced an upcoming podium presentation at the 44th Annual Scientific Meeting of the American Society of Retina Specialists (ASRS), July 15–18, 2026 in Montreal. The talk, “2-Year Follow Up: PRISM Phase 2b Clinical Trial Evaluating Investigational 4D-150, an Intravitreal Gene Therapy, in a Broad Neovascular AMD Population,” will be presented July 18, 2026 (2:58–3:01 p.m. ET) by Carl Awh, MD (Tennessee Retina), and will be posted to the company website.

The announcement highlights 4D-150, being developed for wet age-related macular degeneration (lead indication; Phase 3 development) and diabetic macular edema, designed for multi-year sustained intraocular delivery of anti-VEGF biologics from a single intravitreal injection.

The company also notes 4D-710 in cystic fibrosis, described as demonstrating CFTR transgene delivery and expression in lungs after aerosol delivery.